The potential of TRAIL for cancer chemotherapy

Apoptosis

Volumn 6, Issue 3, 2001, Pages 191-197

  Nagane, M ^a,b   Huang, H J S ^b   Cavenee, W K ^b  

^a KYORIN UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cancer therapy; Death ligand; Death receptor; DNA damage; DR5; TNF superfamily; TNFR superfamily; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELL RECEPTOR; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FAS LIGAND; FLUOROURACIL; IRINOTECAN; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GENOTOXICITY; HUMAN; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

PRIMATES;

EID: 0035001741     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011336726649     Document Type: Article

References (77)

1. Cell death: The significance of apoptosis
2. Caspases: Enemies within
3. Mitochondria and apoptosis
4. Death receptors: Signaling and modulation
5. Apoptosis: Molecular mechanisms and implications for cancer chemotherapy
6. Apoptosis and drug response
7. Mechanisms of apoptosis avoidance in cancer
8. Induction of apoptosis by cancer chemotherapy
9. Apoptosis induced by death receptors
10. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
11. The death receptors
12. Apoptosis signaling by death receptors
13. Apoptosis by death factor
14. Daxx, a novel Fas-binding protein that activates JNK and apoptosis
15. Activation of apoptosis signal-regulating kinase. 1 (ASK1) by the adapter protein Daxx
16. Identification of a ligand for the death-domain-containing receptor Apo3
17. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
18. Fas ligand in human serum
19. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor
20. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
21. Identification and characterization of a new member of the TNF family that induces apoptosis
22. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
23. APO2 ligand: A novel lethal weapon against malignant glioma?
24. Safety and antitumor activity of recombinant soluble Apo2 ligand
25. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
26. The receptor for the cytotoxic ligand TRAIL
27. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
28. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
29. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
30. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
31. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
32. A novel receptor for Apo2L/TRAIL contains a truncated death domain
33. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
34. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
35. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
36. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
37. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
38. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
39. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
40. FADD is required for DR4- and DR5-mediated apoptosis. Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts
41. TRAIL: Receptor-2 signals apoptosis through FADD and caspase-8
42. Human astrocytic brain tumors express AP02L/TRAIL
43. TRAIL: A molecule with multiple receptors and control mechanisms
44. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
45. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
46. Rare loss-of-function mutation of a death receptor gene in head and neck cancer
47. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance
48. Inhibition of death receptor signals by cellular FLIP
49. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
50. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
51. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
52. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis
53. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
54. p53-dependent and-independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
55. p53, the cellular gatekeeper for growth and division
56. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
57. Regulation of p53 downstream genes
58. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression
59. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
60. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
61. The anti-apoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract
62. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis
63. Lethal effect of the anti-Fas antibody in mice
64. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
65. Control of apoptosis signaling by Apo2 ligand
66. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
67. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
68. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
69. Expression of TRAIL and its receptors in human brain tumors
70. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
71. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
72. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
73. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
74. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
75. Steering anti-cancer drugs away from the TRAIL
76. On the TRAIL to a new cancer therapy
77. Human brain-cell death induced by tumor-necrosis factor-related apoptosis inducing ligand (TRAIL)